Positive Data Presented on Pieris Pharmaceuticals' Inhaled

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team

BOSTON, MA --(Marketwired - September 30, 2015) - Pieris Pharmaceuticals, Inc . ( NASDAQ : PIRS ), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, today announced that Professor Gary Anderson, PhD, FThorSoc, FERS, and Director of the Lung Health Research Centre at the University of Melbourne, presented preclinical data on PRS-060, the Company's inhaled IL4Ra antagonist, at a podium presentation during the 2015 annual meeting for the European Respiratory Society (ERS) in Amsterdam, The Netherlands. The Company also announced a key addition to its management team with the appointment of Mary Fitzgerald, PhD, as Vice President of Respiratory Medicine.

In the presentation, entitled "Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1," Professor Anderson provided an overview of the molecular strategy used to re-engineer endogenous human lipocalin-1 into an antagonist of IL4Ra with high affinity, and presented key data demonstrating concentration-dependent antagonism of IL4Ra-mediated signaling, very low in-silico predicted immunogenicity, and technical feasibility for PRS-060 inhalation as a wet aerosol or dry powder. Further, pharmacokinetic analysis demonstrated rapid renal clearance and absence of accumulation, together with allometric dose scaling estimates for inhalation. Dr. Anderson concluded, "these data demonstrate that PRS-060 has a pharmacological and galenical profile well suited for development as a first-in-class inhaled biological for T2-high severe asthma which is driven by the IL4Ra pathway."

"Pieris remains committed to developing highly differentiated next generation therapeutic proteins," commented Stephen Yoder, Pieris President and CEO. "The progress with PRS-060, as reported by Professor Anderson, and the addition of Dr. Fitzgerald to our management team, demonstrate both our commitment to development of novel therapeutics for serious illnesses, as well as our ability to attract industry leadership of the highest caliber to advance our pipeline."

Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development. Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed at Bayer Healthcare for 14 years, most recently as Head of Pharmacology. "I'm excited to lead the development of PRS-060 through IND-enabling studies and into the clinic," noted Dr. Fitzgerald. "As an inhaled targeted therapeutic protein, PRS-060 has the potential to bring a disease-modifying drug to uncontrolled asthma patients where there is a significant unmet medical need, which is an approach that that inhaled or oral small molecules have not been able to address. Importantly, we believe PRS-060 will also deliver a more convenient and effective approach than systemic biologics."

About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin ® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit www.pieris.com .

Forward Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; our liquidity and ability to fund our future operations; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks SVP & Chief Financial Officer +1-603-553-5803 deptula@pieris.com Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com or The Del Mar Consulting Group, Inc. Robert Prag President +1-858-794-5000 bprag@delmarconsulting.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 47

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 34

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading

Top 5 Most Recently Viewed Articles

UROVO Launches Innovative Products to Transform Retail and Warehousing

Updated Category News Views 415

UROVO Launches Innovative Products to Transform Retail and Warehousing At EuroCIS 2025, UROVO, a leading name in industry applications, has unveiled four cutting-edge products: the UHF RFID Sled RFG91, Lightweight UHF RFID Handheld Reader DT50P Lite, Wireless Barcode Scanner K180, and Wearable Computer U2S. These innovations are set to revolutionize retail and warehouse...

Continue Reading
Ameren Corporation Launches New Stock Offering Initiative

Updated Category News Views 331

Ameren Corporation Unveils New Stock Offering In a strategic move to bolster its financial position, Ameren Corporation (NYSE: AEE) has announced the pricing of a significant underwritten offering of common stock. The company is set to offer 5,550,416 shares at an attractive public price of $94.00 each. This offering is aimed at facilitating various corporate financial...

Continue Reading
Exciting Developments: 2025 Bank of America Chicago Marathon

Updated Category News Views 224

Discover the 2025 Bank of America Chicago Marathon Lineup Chicago is gearing up for a thrilling marathon experience as the Bank of America Chicago Marathon announces its professional field for the upcoming event. Scheduled for 2025, the marathon promises to attract some of the world’s most elite runners, including notable champions from previous years. Elite Men Runners...

Continue Reading
Exploring Opportunities and Innovations at ASI Show 2025

Updated Category News Views 157

ASI Show 2025 Unveils Trends and Insights in Promotional Products The Advertising Specialty Institute just wrapped up an exciting event, showcasing the latest in promotional products and networking at the ASI Show 2025 in Fort Worth. Distributors and suppliers gathered from around the globe, eager to engage in meaningful discussions amidst challenges faced by the...

Continue Reading
Canada Nickel's Remarkable Nickel Mineralization Discovery

Updated Category News Views 139

Canada Nickel Announces Significant Exploration Results Canada Nickel Company Inc. (TSXV: CNC) is thrilled to share the latest updates from its exploration efforts at the Reid Nickel Sulphide Project. This recent phase of drilling has uncovered astonishing intervals of nickel mineralization, marking a pivotal moment for this promising mining venture. The discoveries are...

Continue Reading